2023788-19-2

• 常用中文名：替尔泊肽
• 常用英文名：Tirzepatide
• CAS号：2023788-19-2
• 分子式：C₂₂₅H₃₄₈N₄₈O₆₈
• 分子量：4813.45
• 相关类别： 信号通路 G 蛋白偶联受体/G 蛋白 胰高血糖素受体
• 发布时间：2019-06-01 22:19:09
• 更新时间：2026-08-04 12:13:12
• Tirzepatide (LY3298176) 是葡萄糖依赖性胰岛素营养多肽 (GIP) 和胰高血糖素样肽-1 (GLP-1) 受体双重激动剂,正在开发用于治疗 2 型糖尿病。与杜拉鲁肽相比,Tirzepatide (LY3298176) 在血糖控制和体重减轻方面的疗效明显更好。

名称

• 中文名: Tirzepatide
• 英文名: Tirzepatide
• 中文别名: 泰瑞帕肽,替尔泊肽; 替尔泊肽,TIRZATIDE; LY3298176 钠盐 批次2; Tirzatide替尔泊肽; 替西帕肽; 替尔帕肽; TIRZATIDE (LY3298176) ELISA 试剂盒; 替尔珀肽; 替尔泊肽 泰瑞帕肽; DIVBIO/深创生物 替尔泊肽, Tirzatide; 替泽帕肽; 2 替尔泊肽; 替尔泊肽 (LY3298176) ELISA 试剂盒; 替尔泊肽1; 替西帕肽/替尔泊肽/泰瑞帕肽; 替尔泊肽(中间体) Tirzatide Tirzatide Intermediates 替尔泊肽粗肽 Tirzatide Crude Ptide替西帕肽; 新型双重GIP\GLP-1; 替西帕肽/ 替尔泊肽; 泰瑞帕肽(LY3298176); 泰瑞帕肽; 替尔泊肽 试剂盒; TIRZATIDE肽; 替尔泊肽(钠盐); 替尔泊肽/替西帕肽/泰瑞帕肽
• 英文别名: Tirzatide (LY3298176) ，P1206; Tirzatide (LY3298176) ELISA Kit; Tirzatide sodium salt; Tirzatide; tirztide TR10; Gip\GLP-1 Tirzatide Ly3298176 Ptide; Tirzatide (LY3298176); terzapitide; Tirzaptide; Trizatide; Tilpotide; Tirzatide(GLP-1); High-Purity Tirzatide; Tirzpatide; Tiantine Sodium, Tiantine,Tiantine Sodium API, Tiantine API, GLP-1, GLP-1 API, Tiantine Powder, Ptide, Ptide API; Tirzatide powder; Rabbit Anti-Tirzatide pAb; Tirzatide for; ade Tirzatide; Trizatide ptide; Tirzatide High Quality; GLP-1 RA; Tirzatide Lyophilized Powder; Tirzatide WholeSale High Quality; Tirzatide sodium salt (LY3298176); Tirzatide 500mcg Tablets; GIP\GLP-1; Tilposide; Recombinant Tirzatide Protein, N-His-KSI; Anti-Tirzatide Polyclonal Antibody; Tirzatide (Acetate form); Follistatin 344; Tirzatide American Wehouse Cosmetic Ptide for Loss Weight; 13C,15N Tirzatide/Deuterated tirzatide(Tirzatide internal standd); Top Quality Tirzatide; Recombinant Tirzatide Protein, N-GST & C-His; Tirzatide Ptide

物化性质

• 分子式: C₂₂₅H₃₄₈N₄₈O₆₈
• 分子量: 4813.45
• 储存条件: 2-8℃

生物活性

• 描述: Tirzepatide (LY3298176) 是葡萄糖依赖性胰岛素营养多肽 (GIP) 和胰高血糖素样肽-1 (GLP-1) 受体双重激动剂,正在开发用于治疗 2 型糖尿病。与杜拉鲁肽相比,Tirzepatide (LY3298176) 在血糖控制和体重减轻方面的疗效明显更好。
• 相关类别:
  研究领域 >> 代谢疾病
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 胰高血糖素受体
• 参考文献:

  [1]. Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193.

  [2]. Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193.